Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
The chart shows the growth of an initial investment of $10,000 in Medifast, Inc., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Medifast, Inc. (MED) has returned -3.09% so far this year and -18.94% over the past 12 months. Looking at the last ten years, MED has achieved an annualized return of -10.04%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Medifast, Inc. (MED) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 7.02% | -6.90% | -1.45% | 1.57% | ||||||||
| 2025 | -11.65% | -6.99% | -6.13% | -2.38% | 7.08% | 0.07% | -1.64% | 2.18% | -2.36% | -11.68% | -8.28% | -2.11% |
| 2024 | -18.70% | -27.21% | -4.89% | -28.46% | -5.92% | -15.72% | 0.64% | -16.09% | 4.76% | -3.67% | 5.98% | -9.46% |
| 2023 | -4.70% | 0.98% | -7.38% | -12.00% | -14.04% | 17.52% | 10.51% | -16.60% | -12.58% | -7.59% | -3.80% | 1.39% |
| 2022 | -4.95% | -7.00% | -7.96% | 3.40% | -6.50% | 3.53% | -5.54% | -25.75% | -12.29% | 7.33% | 5.91% | -8.86% |
| 2021 | 19.52% | 7.00% | -17.65% | 5.44% | 45.18% | -15.37% | -0.20% | -20.87% | -16.13% | 0.85% | 4.19% | -0.21% |
| 2020 | -11.55% | -14.84% | -25.07% | 24.19% | 37.54% | 34.73% | 19.40% | -3.14% | 1.03% | -14.85% | 42.58% | -4.81% |
| 2019 | 3.78% | -0.20% | -0.13% | 14.36% | -12.36% | -0.59% | -14.00% | -10.45% | 4.43% | 6.58% | -20.86% | 24.64% |
| 2018 | -1.67% | -7.11% | 46.52% | 7.19% | 45.95% | 8.89% | 7.20% | 32.66% | -4.09% | -5.20% | -30.14% | -17.13% |
| 2017 | 0.33% | 6.03% | -1.68% | 4.21% | -10.61% | -0.26% | 2.64% | 31.92% | 4.82% | 4.61% | 9.58% | 1.88% |
| 2016 | 4.75% | 0.92% | 4.52% | 6.12% | 4.55% | 2.72% | 8.42% | -4.71% | 6.99% |
The charts below present risk-adjusted performance metrics for Medifast, Inc. (MED) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of MED compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Medifast, Inc. volatility is 2.54%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 247.97M | 284.21M | 309.91M | 316.21M | 398.33M | 276.08M | 194.65M | 169.43M | 145.93M | 121.22M | 117.33M | 115.91M | 132.65M | 130.25M | 105.67M |
| Equity Attributable To Parent (USD) | 198.92M | 210.11M | 201.48M | 155.04M | 202.47M | 157.25M | 104.83M | 109.11M | 108.58M | 96.02M | 88.58M | 80.48M | 98.42M | 90.79M | 73.40M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 198.92M | 210.11M | 201.48M | 155.04M | 202.47M | 157.25M | 104.83M | 109.11M | 108.58M | 96.02M | 88.58M | 80.48M | 98.42M | 90.79M | 73.40M |
| Noncurrent Liabilities (USD) | 6.09M | 9.94M | 16.13M | 20.28M | 26.02M | 7.49M | 10.43M | - | 208.00K | 779.00K | 5.18M | 8.49M | 7.13M | 10.72M | 12.01M |
| Current Liabilities (USD) | 42.96M | 64.16M | 92.30M | 140.89M | 169.83M | 111.35M | 79.39M | 60.32M | 37.14M | 24.42M | 23.56M | 26.94M | 27.10M | 28.75M | 20.26M |
| Liabilities (USD) | 49.05M | 74.10M | 108.43M | 161.17M | 195.85M | 118.84M | 89.82M | 60.32M | 37.35M | 25.20M | 28.74M | 35.43M | 34.23M | 39.47M | 32.26M |
| Other Non-current Assets (USD) | 15.06M | 32.28M | 34.41M | 36.24M | 35.33M | 14.14M | 14.46M | 4.16M | 2.12M | 166.00K | 224.00K | 519.00K | 360.00K | 1.14M | 1.82M |
| Intangible Assets (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | 428.00K | 1.00M |
| Fixed Assets (USD) | 31.23M | 37.53M | 51.47M | 57.19M | 56.13M | 27.63M | 26.04M | 19.75M | 18.61M | 19.75M | 29.03M | 33.48M | 40.34M | 40.11M | 38.85M |
| Noncurrent Assets (USD) | 46.29M | 69.81M | 85.88M | 93.43M | 91.46M | 41.77M | 40.50M | 23.91M | 20.73M | 19.92M | 29.25M | 34.00M | 40.70M | 41.68M | 41.68M |
| Other Current Assets (USD) | 15.10M | 6.36M | 20.28M | 16.24M | 126.82M | 180.92M | 105.38M | 106.63M | 105.87M | 82.99M | 74.74M | 66.18M | 73.90M | 67.77M | 44.02M |
| Inventory (USD) | 20.23M | 42.42M | 54.59M | 118.86M | 180.04M | 53.39M | 48.77M | 38.89M | 19.33M | 18.31M | 13.34M | 15.74M | 18.06M | 20.80M | 19.97M |
| Cash (USD) | 166.35M | 165.62M | 149.16M | 87.69M | - | - | - | - | - | - | - | - | - | - | - |
| Current Assets (USD) | 201.68M | 214.40M | 224.03M | 222.78M | 306.87M | 234.31M | 154.15M | 145.52M | 125.20M | 101.30M | 88.07M | 81.91M | 91.95M | 88.58M | 63.99M |
| Assets (USD) | 247.97M | 284.21M | 309.91M | 316.21M | 398.33M | 276.08M | 194.65M | 169.43M | 145.93M | 121.22M | 117.33M | 115.91M | 132.65M | 130.25M | 105.67M |
The global consumer healthcare market is experiencing a structural shift where regulatory compliance and FDA approval have become critical competitive advantages. Major companies including Philip Morris, Celsius Holdings, USANA Health Sciences, and Medifast are advancing strategic initiatives focused on regulatory readiness, product integration, and market expansion. Doseology Sciences has partnered with McKinney Regulatory Science Advisors to strengthen its FDA pathway for oral pouch products.
The global weight management market is valued at USD 39.07 billion in 2025 and is projected to reach USD 60.48 billion by 2030, growing at a 7.6% CAGR. Growth is driven by rising obesity prevalence, digital platform adoption, and a shift toward holistic, sustainable weight management programs. North America leads the market while Asia-Pacific is the fastest-growing region.
The global plant-based beverage market is expected to reach $56.73 billion by 2034, growing at a CAGR of 11.9%. Factors driving this growth include increasing health concerns, the popularity of plant-based diets, and environmental considerations.
Post Holdings reported better-than-expected Q4 earnings but missed revenue estimates. The company's shares have outperformed the market so far this year, and its earnings outlook is mixed, leading to a Zacks Rank #3 (Hold).
Medifast (MED) battles persistent customer acquisition challenges aggravated by macroeconomic factors and the rising popularity of weight loss medications.
Medifast's (MED) first-quarter results reflect challenges related to a decline in active earning OPTAVIA Coaches, lower coach productivity and soft sales volume.
This article discusses the upcoming events in the financial world, including the Federal Reserve meeting, corporate earnings, IPOs, and investor events.
Medifast (MED) adapts to shifting consumer behavior to maintain its relevance. However, it is facing difficulties in attracting customers due to the rapidly changing economy and inflation.
MEDIFAST (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medifast (MED) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
